How Covid-19 has Changed the eCOA/ePRO Landscape

How Covid-19 has Changed the eCOA/ePRO Landscape
December 23, 2020 YPrime

During the height of COVID-19, the life science industry had to decide whether to suspend, modify, or cancel their existing clinical trials and had to reprioritize their 2020 pipelines, which of course had been years in the planning.

COVID-19 initially affected the electronic clinical outcome assessment (eCOA) and electronic patient reported outcome (ePRO) components for clinical trials that were ongoing when the pandemic began. However, sponsors who were already using eCOA in their clinical trials may have had an easier time of it, finding it was less of a lift to keep their eCOA data flowing.

In this webinar, Donna M. Mongiello talks about how COVID-19 changed the eCOA/ePRO landscape—the challenges experienced and changes implemented to continue seamless eCOA and ePRO data collection for these trials.

Watch the webinar to learn more about the growing importance of eCOA and ePRO.

WEBINAR

How Covid-19 has Changed the eCOA/ePRO Landscape

Donna M. Mongiello, RN, BSN Vice President, Strategic Solutions

RELATED CONTENT

Getting Better Together Initiative eCOA Lexicon

Getting Better Together Initiative eCOA Lexicon

How to Get the Most Out of Your eCOA Data

How to Get the Most Out of Your eCOA Data

Is BYOD right for your  eCOA Clinical Trial?

Is BYOD right for your eCOA Clinical Trial?

LATEST CONTENT

Effective Use of IRT in Decentralized and Hybrid Clinical Trials

Effective Use of IRT in Decentralized and Hybrid Clinical Trials

Improving DCT Technologies for Efficient and Personalized Delivery

Improving DCT Technologies for Efficient and Personalized Delivery

The Importance of IRT in the Decentralized Clinical Trial Landscape

The Importance of IRT in the Decentralized Clinical Trial Landscape